Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells

Flumens, Donovan; Gielis, Sofie; Bartholomeus, Esther; Campillo-Davo, Diana; van der Heijden, Sanne; Versteven, Maarten; De Reu, Hans; Smits, Evelien; Ogunjimi, Benson; Laukens, Kris; Meysman, Pieter; Lion, Eva

doi:10.1016/bs.mcb.2023.08.001

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the volume of data generated by TCR sequencing is substantial, and the identification of specific TCRs for cancer therapy is time consuming ( 19 ). Novel prediction models have been developed to identify epitope-specific TCRs ( 90 ). In addition, more sensitive and cost-effective sequencing tools have been developed, including characterizing TCR repertoires ( 91 ), spatially resolved TCR sequencing ( 92 ), and formalin-fixed paraffin-embedded-suitable unique molecular identifier-based-TCR sequencing ( 93 ).…”

Section: Conclusion and Prospectsmentioning

confidence: 99%

Exploring the potential of the TCR repertoire as a tumor biomarker (Review)

Huang,

He,

Yang

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

T cells play an important role in adaptive immunity. Mature T cells specifically recognize antigens on major histocompatibility complex molecules through T-cell receptors (TCRs). As the TCR repertoire is highly diverse, its analysis is vital in the assessment of T cells. Advances in sequencing technology have provided convenient methods for further investigation of the TCR repertoire. In the present review, the TCR structure and the mechanisms by which TCRs function in tumor recognition are described. In addition, the potential value of the TCR repertoire in tumor diagnosis is reviewed. Furthermore, the role of the TCR repertoire in tumor immunotherapy is introduced, and the relationships between the TCR repertoire and the effects of different tumor immunotherapies are discussed. Based on the reviewed literature, it may be concluded that the TCR repertoire has the potential to serve as a biomarker for tumor prognosis. However, a wider range of cancer types and more diverse subjects require evaluation in future research to establish the TCR repertoire as a biomarker of tumor immunity.

show abstract